LOGIN  |  REGISTER
Amneal Pharmaceuticals

LeMaitre Vascular to Participate at Upcoming Investor Conferences in December

November 25, 2024 | Last Trade: US$94.48 0.54 -0.57

BURLINGTON, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in December.

David Roberts, President, will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at the Lotte New York Palace in New York City. The company’s presentation is scheduled for 3:30 PM EST.

He is also scheduled to present at the Stifel “MedTech Madness” West Coast Bus Tour at the Rosewood Sand Hill in Menlo Park, CA on Thursday, December 12, 2024, at 11:45 AM PST.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

Contact:
Gregory Manker
Director, Business Development & Investor Relations
LeMaitre Vascular, Inc.
+1-781-362-1260
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page